International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(11), P. 5095 - 5095
Published: May 26, 2025
Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality, necessitating the identification novel biomarkers for improved prognosis and diagnosis. This study investigates role epoxide hydrolase 4 (EPHX4), member family, in LUAD. Using data sourced from The Cancer Genome Atlas (TCGA) Genotype-Tissue Expression (GTEx) databases, which were subsequently validated by Gene Omnibus (GEO), we analyzed levels EPHX4 expression, mutation, methylation tumors versus normal tissues. Our findings revealed significant upregulation LUAD tissues compared to lung (p < 0.001), correlating with poorer overall survival (OS), disease-specific (DSS), progression-free interval (PFI). Furthermore, exhibited considerable diagnostic potential, as demonstrated an area under curve (AUC) 0.854 Receiver Operating Characteristic (ROC) analysis. Notably, expression was associated immune infiltration, specifically Th2 cells, neutrophils, macrophages, along checkpoint molecules including PD-L1, PD-L2, TIM-3. Additionally, involved pivotal tumor-associated pathways, particularly cell cycle regulation. In conclusion, elevated is indicative may play evasion dysregulation, highlighting its potential promising biomarker diagnosis prognostic prediction
Language: Английский